| Q33437824 | A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. |
| Q33414164 | Bone marrow examination in patients with immune thrombocytopenia: is there anything different in older patients? |
| Q33421379 | Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study |
| Q33397092 | Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents |
| Q33420059 | Romiplostim as a treatment for immune thrombocytopenia: a review |
| Q33405989 | Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications |
| Q33396730 | Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities |
| Q33421014 | United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings |